Nightstar Therapeutics has agreed to be acquired by Biogen.
News
EMA accepts marketing authorisation applications for Idefirix and Xospata
European regulators have accepted for review marketing authorisation applications for Hansa’s Idefirix and Astellas’ Xospata.
Eight medicines recommended in final London CHMP meeting
The first treatment for a rare disease characterised by high levels of triglycerides in blood is among eight new medicines put forward by the European Medicines Agency’a human medicines committee (CHMP) for approval.
Feraccru hits endpoints in anaemia trial
Oral iron replacement therapy Feraccru has been shown to have comparable efficacy to intravenously delivered Ferinject in patients with Iron Deficiency Anaemia, offering a “real” alternative to hospital administration for many patients.
Integrated NHS leadership team is ‘right move’
NHS Improvement and NHS England have shaken up their leadership team.
Napp launches pegfilgrastim biosimilar in the UK
Napp Pharmaceuticals has launched Pelmeg – a pegfilgrastim biosimilar – across the UK.
New research into chest pain to reduce stress on ambulance crews and A&E
New research is being undertaken to determine whether paramedics can safely assess and manage patients with chest pain without them necessarily having to go to hospital, providing early reassurance as well as reducing stress on ambulance crews and A&E departments.
Oxford Genetics wins six licensing deals
Oxford Genetics has won six new licensing deals for its scalable gene therapy manufacturing technologies.
NHS Improvement makes ‘important’ chief people officer appointment
NHS Improvement has appointed Prerana Issar as its new chief people officer.
Horizon’s teprotumumab hits major R&D milestone
Horizon Pharma has announced positive Phase III clinical trial data for teprotumumab, as a treatment for active thyroid eye disease (TED).
Amryt’s epidermolysis bullosa trial extended
Amryt’s AP101 EASE Phase III trial has been extended to include infants aged 21 days to four years.
Novavax’ ResVax flops in late-stage study
A late-stage study of Novavax’ respiratory syncytial virus vaccine ResVax has failed to hit its main goal.
Innovate UK and Asthma UK to fund joint projects
Innovate UK and Asthma UK are joining forces to improve treatment for asthma.
Cell mechanism that repairs potentially cancerous DNA damage discovered
Researchers have discovered a cell mechanism that repairs potentially cancerous DNA damage.
Novartis, Blackstone Life Sciences launch new biotech
Novartis has teamed up with biopharmaceutical investor Blackstone Life Sciences to launch a new biotech start up, Anthos Therapeutics.
